secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANGIODYNAMICS INC (ANGO)
CIK:        0001275187
Form:       8-K
Filed at:   2026-10-08T11:17:49+00:00
Accession:  0001140361-26-039020
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

AngioDynamics Q1 FY27 sales rise 6.9% to $80.9M; adjusted loss narrows to $0.04, FY27 guidance reiterated
--------------------------------------------------------------------------------

- Net sales $80.9M, up 6.9% YoY; Med Tech $39.9M (+13.2%) and Med Device $41.0M (+1.4%); GAAP loss per share $0.17 vs $0.26 a year ago.
- Adjusted loss per share $0.04 vs $0.10; adjusted EBITDA $5.0M vs $2.2M; gross margin 59.4% (+410 bps), or 57.8% excluding tariff refunds; $34.0M cash, debt-free.
- Auryon sales $18.9M (+14.7%), NanoKnife $8.3M (+29.0%), AlphaVac +37.4%, AngioVac -5.9%; Mechanical Thrombectomy $12.0M (+6.7%).
- FY27 guidance reiterated: net sales $336-341M, Med Tech growth 12-15%, Med Device flat, gross margin 54-55%, adjusted EBITDA $13-16M, adjusted EPS -$0.29 to -$0.24.
- Eric Honroth named President and CEO effective Nov 2, 2026, succeeding retiring Jim Clemmer; FDA IDE approved for RELIEF, a 40-patient NanoKnife IRE study in BPH.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1275187/000114036126039020/0001140361-26-039020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1275187/000114036126039020/ef20083493_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-039020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer